1 / 5

Watch Out for the Most Promising Therapies in the Pipeline in ARDS Market

Watch Out for Acute respiratory distress syndrome Treatment includes nutritional support, therapy for the underlying injury, and supportive measures such as mechanical ventilation, prevention of stress ulcers, and venous thromboembolism. Strong positive end-expiratory pressure, careful fluid management, and low tidal volumes may improve outcomes.the Most Promising Therapies in the Pipeline in ARDS Market

xmichael
Download Presentation

Watch Out for the Most Promising Therapies in the Pipeline in ARDS Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Watch Out for the Most Promising Therapies in the Pipeline in ARDS Market ARDS Market Therapies and Pipeline Assessment Critically ill patients who have acute respiratory distress syndrome (ARDS) are affected by this quickly advancing disease. Breathing becomes difficult or impossible due to fluid spilling into the lungs, which is the main consequence of ARDS. ARDS symptoms include shortness of breath, coughing, and fever; in some instances, high heart rates and rapid breathing have also been noted. Due to significantly lower blood oxygen levels, patients with ARDS may have chest pain, especially during inhalation, and some may also have blue lips and nails. The critically ill patients—who made up just 1%–4% of all COVID-19 cases—made up the potential pool for ARDS. Acute respiratory distress syndrome Treatment includes nutritional support, therapy for the underlying injury, and supportive measures such as mechanical ventilation, prevention of stress

  2. ulcers, and venous thromboembolism. Strong positive end-expiratory pressure, careful fluid management, and low tidal volumes may improve outcomes. Identifying any underlying infections and treating them with medicines that target cultural sensitivities is crucial. There are few ARDS therapy options available despite decades of research. Supportive care, along with mechanical ventilation, forms the basis of management. The ARDS market has a limited selection of ARDS treatments. Further oxygen, prone positioning, paralytics, fluid management, and a technique known as positive end-expiratory pressure (PEEP) to help drive fluid out of air sacs are all additional ARDS therapy options for patients. These are utilized in addition to continued ARDS care for the original sickness or damage. The drug Actemra/RoActemra (tocilizumab for the treatment of ARDS in hospitalized adults and pediatric patients (2 years of age and older) receiving systemic corticosteroids and requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation) has been given an emergency use authorization (EUA) by the Food and Drug Administration (ECMO). Outside of the present phase II trial, Pluristem Therapeutics' Expanded Access Program (EAP) uses its PLX-PAD cells to treat ARDS brought on by COVID-19. FDA approval was also granted for COVID-19 studies conducted in the US. None of the ARDS drugs now on the market treat decreased lung function; they only effectively treat ARDS-related inflammation. Leading pharmaceutical firms like MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, and Healios, as well as APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, and ILTOO Pharma, and others. Emering Therapies in the ARDS Market 1. Drug: Remestemcel-L ● ● ● ● Company: Mesoblast Phase: Phase III MoA: Cell replacements Special Designation: Fast Track Designation (US) 2. Drug: EB05 ● ● ● Company: Edesa Biotech/Light Chain Bio Phase: Phase II/III MoA: Toll-like receptor 4 antagonists 3. Drug: MultiStem

  3. ● ● ● Company: Athersys/Healios Phase: Phase II/III MoA: Cell replacements 4. Drug: Alteplase ● ● ● Company: Boehringer Ingelheim/Genentech Phase: Phase II/III MoA: Fibrinolytic agents; Plasminogen activator stimulants; Plasminogen activators 5. Drug: BIO-11006 ● ● ● Company: BioMarck Pharmaceuticals Phase: Phase II MoA: Myristoylated alanine-rich C kinase substrate inhibitors 6. Drug: Lucinactant ● ● ● Company: Windtree Therapeutics Phase: Phase II MoA: Cell membrane permeability enhancers 7. Drug: Solnatide ● ● ● Company: Apeptico Forschung und Entwicklung GmbH Phase: Phase II MoA: Sodium channel agonists Future Perspectives in the ARDS Market High-priced drugs like stem cell treatments and other pipeline candidates with stronger clinical profiles are anticipated to dominate the ARDS market. Different pharmaceutical companies are evaluating and researching several compounds to improve the ARDS pipeline and increase the likelihood of immediate successful treatment. Drug research and development is encouraged by the increase in ARDS prevalence since it will probably create a favorable environment for the commercial success of novel medications. The ARDS market is anticipated to have a significant demand for prospective new therapeutics with a better clinical profile in the future because no medication has been licensed. The market for ARDS treatment market is therefore anticipated to grow in the next years due to all these factors. Related Reports: Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology,

  4. Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Ventricular Assist Devices (VAD) Market Ventricular Assist Devices (VAD) Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022 To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services

  5. Also, take a glance at the Blogs by DelveInsight: ● ● ● ● How Metaverse is Set to Transform the Healthcare Dynamics? Role of Mobile Technology in Hemophilia Management How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry? How Cloud Computing is Transforming the Healthcare Industry Dynamics?

More Related